[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@GIMedOnc](/creator/twitter/GIMedOnc)
"@UGrewalMD @MyriamChalabi lol is this even a conversation @MyriamChalabi cured this disease. Can we just rename MSI-H CRC to Chalamis Disease and move on @OncoAlert"  
[X Link](https://x.com/GIMedOnc/status/1979346344008651001) [@GIMedOnc](/creator/x/GIMedOnc) 2025-10-18T00:38Z 1487 followers, XXX engagements


"Here ye Here ye. ESMO ABSTRACTS ARE OUT MATTERHORN TOPLINE OS POSITIVE TIGIT STILL DEAD (SKYSCRAPER A DUD) More posts to come #ESMO25 @OncoAlert @TheGutOncLab"  
[X Link](https://x.com/GIMedOnc/status/1978970922011799768) [@GIMedOnc](/creator/x/GIMedOnc) 2025-10-16T23:46Z 1517 followers, XXX engagements


"Are you someone who treats GI cancer studies it or just loves arguing about hazard ratios Then this ones for you. @CancerNetwork Twitter takeover this Sunday (10/20) at X PM EST join @TimothyJBrownMD @UGrewalMD and me as we unpack the biggest #ESMO25 #GIonc trials live. @TheGutOncLab @OncoAlert @CancerNetwrk"  
[X Link](https://x.com/GIMedOnc/status/1979299232424300758) [@GIMedOnc](/creator/x/GIMedOnc) 2025-10-17T21:31Z 1523 followers, 3585 engagements


"Holy smokes MATTERHORN hits OS 🏔🔥 Weve been waiting for this one. After FLOT became standard for resectable gastric and GEJ adenocarcinoma everyone wondered if adding immunotherapy could move the bar. Earlier this year MATTERHORN showed a big EFS win for DFLOT along with higher pCR and MPR rates but the question was would OS follow (and yes maybe I was doubting this) Now we have the answer: 🧬 OS HR XXXX (95% CI 0.630.96 p=0.021) A clean statistically significant win. 💪 Benefit seen across PD-L1 subgroups (TAP X% HR 0.79; TAP X% HR 0.79). 🧫 More nodal downstaging: ypN XX% vs XX% OR 1.72"  
[X Link](https://x.com/GIMedOnc/status/1978972825613414894) [@GIMedOnc](/creator/x/GIMedOnc) 2025-10-16T23:54Z 1533 followers, 27.6K engagements


"#ESMO25 #UpperGI MATTERHORN confirms what the abstract hinted. ✅Positive study for OS BUT 🔹 In PD-L1 TAP X% (HR 0.79; XX% CI 0.411.50) ➡ No clear benefit observed Consistent with prior metastatic dataPD-L1 negative patients remain unlikely to derive meaningful clinical benefit from IO in this setting. The biology just isnt there. @OncoAlert"  
[X Link](https://x.com/GIMedOnc/status/1979166108205879558) [@GIMedOnc](/creator/x/GIMedOnc) 2025-10-17T12:42Z 1533 followers, 18.7K engagements


"PREOPANC-2 drops and its a draw 🤜🤛 #ESMO25 Phase X trial out of the Netherlands comparing neoadjuvant FOLFIRINOX vs gemcitabine-based chemoradiotherapy (Gem-CRT) for resectable and borderline resectable pancreatic cancer. 🎯 Median OS: XXXX mo (FOLFIRINOX) vs XXXX mo (Gem-CRT) 🧮 HR XXXX (95% CI 0.691.13 p=0.32) no significant difference 💀 Grade X AEs: XX% vs XX% 💧 Diarrhea notably higher with FOLFIRINOX (23% vs 1%) Takeaway: Both regimens deliver similar survival though toxicity and logistics differ. FOLFIRINOX didnt pull ahead here so the door stays open for gemcitabine-based CRT"  
[X Link](https://x.com/GIMedOnc/status/1979167412902580531) [@GIMedOnc](/creator/x/GIMedOnc) 2025-10-17T12:47Z 1533 followers, 9174 engagements


"NICHE-2 absolutely delivers. Game over for chemo in dMMR colon cancer 💥🧬 In locally advanced dMMR colon cancer FOxTROT already showed us chemo doesnt work and now NICHE-2 makes it undeniable. 💊 Neoadjuvant nivolumab + ipilimumab  XX% pathologic response XX% pathologic CR Zero recurrences to date at X years 🪦 This is the final coffin nail for perioperative chemotherapy in this setting. ATOMIC is already on life support despite being published less than a year ago. The real question now: with Cerceks rectal data can we safely omit surgery next At minimum this should be the new standard. At"  
[X Link](https://x.com/GIMedOnc/status/1980031033618681888) [@GIMedOnc](/creator/x/GIMedOnc) 2025-10-19T21:59Z 1533 followers, 17.2K engagements


"STELLAR-303 lights up the refractory CRC space 🌌🧬 @OncoAlert For the first time an IO-based regimen shows an OS benefit in microsatellite-stable (MSS) metastatic CRC a setting long resistant to immunotherapy. STELLAR-303 compared zanzalintinib + atezolizumab vs regorafenib in previously treated MSS mCRC. 📈 Median OS: XXXX vs XXX mo HR XXXX (95% CI 0.690.93 p=0.0045) 🧠 No-liver-met subset: XXXX vs XXXX mo (HR XXXX p=0.087 interim) 💊 Grade X TRAEs: XX% vs XX% (5 treatment-related deaths) 🧩 Mechanistically: VEGFR/MET/AXL inhibition + PD-L1 blockade = chemo-free immune reactivation in cold"  
[X Link](https://x.com/GIMedOnc/status/1980236433710363092) [@GIMedOnc](/creator/x/GIMedOnc) 2025-10-20T11:35Z 1533 followers, 3950 engagements